Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryBlue Cross MA eyelid thermal pulsation Coverage | …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 613

    Eyelid Thermal Pulsation Therapy (Investigational / Not Covered)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 613 alerts

    Get alerted when Policy 613 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of eyelid thermal pulsation therapy (devices and procedures) to treat meibomian gland dysfunction / dry eye syndrome for Blue Cross Blue Shield Massachusetts members across commercial and Medicare products.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyEyelid Thermal Pulsation Therapy (Investigational / Not Covered)
    Policy CodePolicy 613
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain precertification/preauthorization for inpatient procedures described in this policy; outpatient eyelid thermal pulsation is not covered for specified product lines.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    InvestigationalPolicy stance

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0207T,0330T,0507T,0563TInvestigational codes
    Prior auth requiredInpatient rule
    Not coveredOutpatient coverage
    Through Jan 26, 2026Literature review

    Coverage Determination

    Investigational / Not Covered

    Covered when ALL of the following are met:

    Policy stance: Eyelid thermal pulsation therapy to treat dry eye syndrome is investigational.

    This policy considers the procedure investigational and not medically necessary per policy.

    Outpatient coverage: Outpatient eyelid thermal pulsation is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue.

    Outpatient claims for these product lines will be denied as noncovered.

    Inpatient prior authorization: If the procedure is performed inpatient, precertification/preauthorization is required.

    Absence of required precertification for inpatient services may trigger denial.

    For outpatient settings, eyelid thermal pulsation is not a covered service for the following product lines: Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM. Claims submitted for outpatient eyelid thermal pulsation for members in these product categories are subject to denial because the service is noncovered.

    The policy considers eyelid thermal pulsation therapy to treat dry eye syndrome investigational. As investigational, this therapy is not medically necessary under this policy and is therefore not covered.

    Procedure and Billing Codes

    Investigational CPT CodesCPTNot Covered
    0207TEvacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral.
    0330TTear film imaging, unilateral or bilateral, with interpretation and report.
    0507TNear-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report.
    0563TEvacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral.
    Investigational CPT Codes (duplicate group for display compatibility)CPTNot Covered
    0207TEvacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral.
    0330TTear film imaging, unilateral or bilateral, with interpretation and report.
    0507TNear-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report.
    0563TEvacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral.

    Provider Requirements and Operational Notes

    Prior Authorization

    Inpatient procedures require precertification

    Precertification/preauthorization is required for services described in this policy when the procedure is performed inpatient.

    Note

    Outpatient eyelid thermal pulsation is noncovered

    Eyelid thermal pulsation performed in the outpatient setting is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue, and Medicare PPO Blue; prior authorization is not applicable for these noncovered outpatient services.

    Step Therapy

    Conservative therapies for MGD

    Conservative therapies for meibomian gland dysfunction cited in the policy include warm compresses, eyelid scrubs, manual/physical expression, and medications (for infection/inflammation); the policy notes these are existing treatment options but does not establish a formal step-therapy algorithm.

    Clinical Background

    Dry eye syndrome, including meibomian gland dysfunction (MGD), is a common ocular surface disorder that causes irritation and visual disturbance and increases in prevalence with age. MGD — a dysfunction of the meibomian glands — is recognized as the most common cause of evaporative dry eye. Symptoms and gland obstruction can lead to reduced tear-film stability and ocular surface inflammation, prompting a range of conservative management options such as warm compresses, eyelid hygiene, manual gland expression, and medications.

    Thermal pulsation treatments apply heat to the palpebral eyelids and use pulsatile pressure to express meibomian glands; while this is an available treatment approach, the policy evaluates it as investigational and does not consider it established medical necessity.

    Key Definitions

    Thermal pulsation / eyelid thermal pulsation — definition and description
    DefinitionA treatment applying heat to the palpebral surfaces of the upper and lower eyelids directly over the meibomian glands while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces to express the glands.
    Procedure descriptionDelivers heat to eyelid surfaces and intermittent/pulsatile pressure to evacuate meibomian gland contents (express the glands).
    Intended targetMeibomian glands within the upper and lower eyelids to relieve gland obstruction and improve tear film lipid layer.
    Clinical roleUsed as a therapeutic option for meibomian gland dysfunction to address evaporative dry eye by expressing gland contents.
    Meibomian gland dysfunction (MGD) — definition and relation to dry eye
    Definition
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyEyelid Thermal Pulsation Therapy (Investigational / Not Covered)
    Policy CodePolicy 613
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain precertification/preauthorization for inpatient procedures described in this policy; outpatient eyelid thermal pulsation is not covered for specified product lines.
    SourceLink
    On This Page
    Coverage DeterminationProcedure and Billing CodesProvider Requirements and Operational NotesClinical BackgroundKey Definitions
    • Warm compresses to liquefy meibomian gland contents
    • Eyelid scrubs to relieve external gland orifice blockage
    • Physical/manual expression of glands
    • Medications (eg, antibiotics, topical corticosteroids) to treat infection/inflammation
    Documentation Required

    Report services with current procedure, revenue, diagnosis codes and modifiers

    Providers must report services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

    • Use current CPT/HCPCS procedure codes and ICD diagnosis codes
    • Include revenue codes and applicable modifiers per standard billing practice
    Denial Risk

    Outpatient service submission risks denial

    Claims for outpatient eyelid thermal pulsation are subject to denial because the service is not covered for the listed product lines; submitting outpatient claims for this procedure risks claim denial.

    Prior Authorization

    Obtain inpatient prior authorization to avoid denial

    If the procedure is performed inpatient, precertification/preauthorization is required for all products; absence of the required precertification may result in claim denial.

    A dysfunction of the meibomian glands that is considered the most common cause of dry eye syndrome.
    Clinical significanceMGD is recognized as the major cause of dry eye syndrome and contributes to evaporative tear film instability.
    EpidemiologyDry eye affects an estimated 16.4 million Americans; prevalence increases with age and MGD prevalence in studies ranged from 10% to 55%.
    Relation to thermal pulsationThermal pulsation targets MGD by applying heat and pulsatile pressure to express meibomian glands and relieve gland obstruction.